What can patient and public involvement in research contribute to safe and effective use?

Prof. Dr. Isabel Dziobek



Psychische Gesundheit

Classified as public by the European Medicines Agency

Conflict of Interest

Researchs Funding: BMBF, BMWK, DFG, TBDF Lectures: no industry honoraria Consultancy: none Shares: none

Patient and Public Involvement (PPI)

- Academic research typically conducted with no/very little involvement of patients and the public
- Lost opportunity to improve validity, quality and accountability of clinical research
- Rising ethical standards are changing power imbalance between researchers and experts by experience



Patient and Public Involvement (PPI)

What is PPI?

- Research that is done WITH or FROM people with lived experience and not just about or for them. INVOLE, 2012
- Study participation **≠** participatory research



Stage Model of Participation

			_	Level 9	Community-Owned Initiatives	goes beyond participation
				Level 8	Decision-making Authority	Participation
		_	L	evel 7.	Partial Delegation of Decision-making Authority	
			Level 6		Shared Decision- Making	
		L	Level 5		Inclusion	
		Level 4			Consultation	Preliminary Stages of Participation
	Le	Level 3			Information	
	Level 2				Instruction	Non- Participation
Level 1					Instrumentalization	

Figure 2: stage model of participation by M. T. WRIGHT [16] Following the levels of participation of WRIGHT, real

Reasons for PPI

• Because it is ethically and legally indicated

→ UN Convention of Rights of Persons with Disabilities, 2008

Because it makes science better

- \rightarrow identify topics of relevance
- \rightarrow better outcome measures
- \rightarrow Better recruitment, greater diversity
- \rightarrow fewer drop-out
- \rightarrow lower costs
- \rightarrow results reach comunities

 \rightarrow better acceptance and accountability of research



- Because it has positive effects on resarchers and experts of experience
 → mutual respect through perspective taking
- ightarrow new knowledge and skills
- \rightarrow self-confidence and empowerment



- PPI has become new standard
- Essential criteria for research funding bodies
- Duty in governing organizations

PPI in Psychedelic Research

- Almost no realizations of PPI in clinical trials on psychedelics
- Few exceptions: e.g. trials on psilocybin ICL pilot study (AN), EPIsoDE trial (TRD), research on MDMA

Although application here especially appropriate...

- Safety, acceptance and accountability of research of utmost importance (abuse of power in early studies)
- Diversity low in clinical research on psychedelics
- Difficult access for minority groups
- Expectancy bias
- Patient reported outcomes especially appropriate (heterogeneity of experiences and adverse events)



Guidance for PPI in psychedelic research

- Numerous Frameworks/tools to support PPI in general research
- However, psychedelic research needs tailored approach given special context/history:
 - complex socio-political landscape
 - rapidly changing drug policy
 - knowledge from traditions predating modern research
 - social stigma associated with recreational use
 - 20-year hiatus in research

frontiers in Psychiatry


ORIGINAL RESEARCH published: 30 September 2021 doi: 10.3389/fpsyt.2021.727496

Co-design of Guidance for Patient and Public Involvement in Psychedelic Research

James B. Close^{1*}, Julia Bornemann¹, Maria Piggin², Sandra Jayacodi³, Lisa Xiaolu Luan¹, Robin Carhart-Harris¹ and Meg Jo Spriggs¹

¹ Centre for Psychedelic Research, Division of Brain Sciences, Imperial College London, London, United Kingdom, ² Patient Experience Research Centre, Imperial College London, London, United Kingdom, ³ Imperial Biomedical Research Centre Public Panel, London, United Kingdom

PPI Framework for psychedelic research



"Trust has long been placed at the center of guidance related to psychedelic research, in which participants are encouraged to "trust, open, and let go".

In this context, the responsibility lies with the researcher to be trustworthy, rather than a participant to be trusting.

Thank you for your attention!

Classified as public by the European Medicines Agency